UBS Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $640

Benzinga · 2d ago
UBS analyst Michael Yee maintains Vertex Pharmaceuticals (NASDAQ:VRTX) with a Buy and raises the price target from $615 to $640.